Oral bisphosphonates and malignancy.
- 1 August 1997
- journal article
- review article
- Published by AMPCo in The Medical Journal of Australia
- Vol. 167 (4) , 211-212
- https://doi.org/10.5694/j.1326-5377.1997.tb138848.x
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.Journal of Clinical Oncology, 1997
- Clodronate decreases the frequency of skeletal metastases in women with breast cancerBone, 1996
- Effects of oral clodronate on bone mineral density in patients with relapsing breast cancerBone, 1996
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- Randomised, placebo-controlled multicentre trial of clodronate in multiple myelomaThe Lancet, 1992
- Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases—A prospective randomised placebo-controlled multicentre studyEuropean Journal Of Cancer, 1992
- Effect of a single infusion of alendronate in malignant hypercalcaemia: Dose dependency and comparison with clodronateInternational Journal of Cancer, 1992
- BisphosphonatesDrugs, 1991
- COMPARISON OF THREE INTRAVENOUS BISPHOSPHONATES IN CANCER-ASSOCIATED HYPERCALCAEMIAThe Lancet, 1989